Why the study?
Does co-treatment with CYP3A4-metabolized statins (atorvastatin or simvastatin) attenuate the platelet inhibitory effect of clopidogrel compared to a non-CYP3A4 metabolized statin (rosuvastatin) in patients with coronary artery disease?
Population
69 patients with coronary artery disease
Comparison
Atorvastatin or simvastatin co-administered with… vs Rosuvastatin co-administered with clopidogrel 75…
Design
RCT, randomized, double-blind for atorvastatin vs rosuvastatin; open-label for…
Follow-up
2 weeks
Authors
Loading...
Co-administration of atorvastatin or simvastatin does not attenuate clopidogrel's antiplatelet effect; confirms no clinically relevant CYP3A4 interaction in CAD.
Does co-treatment with CYP3A4-metabolized statins (atorvastatin or simvastatin) attenuate the platelet inhibitory effect of clopidogrel compared to a non-CYP3A4 metabolized statin (rosuvastatin) in patients with coronary artery disease?
Co-administration of CYP3A4-metabolized statins (atorvastatin, simvastatin) does not attenuate the antiplatelet efficacy of clopidogrel compared to non-CYP3A4 statins (rosuvastatin).
Malmström et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: